Company Profile
Mirum Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- MIRM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
96.72 USD (+0.43%)
Close
Last updated: August 24, 2026
5.62B USD
Market cap
Why the stock is moving
As of Aug 24, 2026, MIRM closed up 0.43% at $96.72. No new same-company headline was identified in the current news window.
Company overview
Business overview
Mirum Pharmaceuticals is a rare-disease company focused on cholestatic and liver disorders. Its commercial profile is built around specialized therapies for pediatric and orphan indications.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Mirum sits in specialty biopharma.
Business Model Characteristics
The company combines product revenue with label expansion and pipeline growth in liver disease.
Position Within the Biotechnology Landscape
Mirum is a durable rare-disease name whose stock moves on commercial execution and franchise expansion.
Future catalysts
- Mirum's catalysts are Livmarli growth, liver-disease expansion, and any new rare-cholestatic label or commercial step that widens the franchise. The stock improves if the rare-disease base keeps compounding into a broader franchise.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Mirum Pharmaceuticals (MIRM)?
Mirum Pharmaceuticals (MIRM) most recently closed at 96.72 USD, a +0.43% move versus the previous session.
What is the market cap of Mirum Pharmaceuticals (MIRM)?
Mirum Pharmaceuticals currently has a market capitalization of 5.62B USD on BioPharmSignal.
What does Mirum Pharmaceuticals do?
Mirum Pharmaceuticals is a rare-disease company focused on cholestatic and liver disorders. Its commercial profile is built around specialized therapies for pediatric and orphan indications.
On which exchange is MIRM stock listed?
Mirum Pharmaceuticals (MIRM) is associated with NASDAQ, United States, Biopharma.
What is Mirum?
Mirum's catalysts are Livmarli growth, liver-disease expansion, and any new rare-cholestatic label or commercial step that widens the franchise.
Which conditions is Mirum Pharmaceuticals targeting with Mirum?
Mirum's catalysts are Livmarli growth, liver-disease expansion, and any new rare-cholestatic label or commercial step that widens the franchise.
How does Mirum Pharmaceuticals describe recent progress with Mirum?
Mirum's catalysts are Livmarli growth, liver-disease expansion, and any new rare-cholestatic label or commercial step that widens the franchise.
What is Pharmaceuticals?
Mirum Pharmaceuticals is a rare-disease company focused on cholestatic and liver disorders.